We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

AD Protective Gene Represents Promising Therapeutic Target

By LabMedica International staff writers
Posted on 14 Dec 2017
Print article
Alzheimer's disease (AD) researchers have identified a gene variant that is present in a small percentage of individuals with AD risk factors but who exhibit resilience by living well beyond 75 years of age without developing any clinical symptoms of cognitive decline.

Investigators at Brigham Young University (Salt Lake City, UT, USA) used the vast Utah Population Database of genealogical and historical medical records to identify a cohort of over 200 “AD resilient” individuals. They performed linkage analyses of the resilient individuals and then used whole genome sequences to identify candidate SNPs (single-nucleotide polymorphisms) in significant linkage regions. Next, they replicated SNPs from the linkage peaks that reduced risk for AD in an independent dataset and in a gene-based test. Finally, they experimentally characterized replicated SNPs in vitro.

Results published in the November 29, 2017, online edition of the journal Genome Medicine revealed promising variants in the RAB10 (Ras-related protein Rab-10) and SAR1A (secretion associated Ras related GTPase 1A) genes. The resilient subjects shared a variant in the RAB10 gene while those who got the disease did not share the genetic variant. The investigators also found that RAB10 expression was significantly elevated in human AD brains

The RAB10 findings were replicated in two independent series of unrelated individuals and in a gene-based test. Both RAB10 and SAR1A were differentially expressed in human AD brains. Results of in vitro tests to evaluate the biological impact of RAB10 and SAR1A suggested that RAB10 variants were linked to risk for AD, and that RAB10 may represent a promising therapeutic target for AD prevention.

"There are currently no meaningful interventions for Alzheimer disease; no prevention, no modifying therapies, no cure," said senior author Dr. John Kauwe, associate professor of biology at Brigham Young University. "The discoveries we are reporting in this manuscript provide a new target with a new mechanism that we believe has great potential to impact Alzheimer's disease in the future."

Related Links:
Brigham Young University

Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
HDL Subfractions Kit
Lipoprint HDL Subfractions Kit
Automatic Biochemistry Analyzer
Cardiac Test
ImmunTech Cardiac Triple Test

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.